Work

Tumor mutation burden (TMB) and immune-related adverse events (irAEs) compared to antibiotic (abx) use to predict for response to immune checkpoint inhibitors in esophagogastric cancer (EGC).

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.4056

Authors: Megan Greally, Walid K Chatila, Matthew Margolis, Jaclyn Frances Hechtman, Yaelle Tuvy, Ritika Kundra, Marc Ladanyi, David Paul Kelsen, David H. Ilson, Michael F. Berger, Laura H. Tang, David B. Solit, Nikolaus Schultz, Yelena Yuriy Janjigian, Geoffrey Yuyat Ku

Institution: Memorial Sloan Kettering Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2889610596

Cites:

Cited by: 2

Related to: 10